CD8A and neoplasm: Effector anti-tumoral CD8+ T lymphocytes (cytotoxic T cells, CTL) recognize tumor-specific antigens in the form of processed peptides associated with the major histocompatibility complex class I (MHC I) molecules expressed at the surface of cancer cells.